Prometheus Biosciences

company

About

Prometheus Biosciences develops and commercializes pharmaceutical and diagnostic products to help physicians individualize patient care.

Details

Last Funding Type
Private Equity(PE)
Last Funding Money Raised
$130M
Industries
Biotechnology,Health Diagnostics,Pharmaceutical,Therapeutics
Founded date
Jan 1, 1995
Number Of Employee
501 - 1000
Operating Status
Active
Stock Symbol
nasdaq:RXDX
Legal Name
Prometheus Biosciences, Inc.
Also Known As
Prometheus Laboratories

Prometheus Biosciences, Inc., former Prometheus Laboratories, Inc., a specialty pharmaceutical company, engages in developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. It markets and promotes Entocort EC, a glucocorticosteroid, which is indicated for the induction and maintenance of clinical remission in mild to moderately active Crohn's disease involving the ileum and/or the ascending colon. It has an agreement to acquire rights to LOTRONEX tablets, which is used in female patients with diarrhea-predominant irritable bowel syndrome; and an agreement to develop and commercialize COLAL-PRED, a development-stage product for the treatment of gastrointestinal diseases or other applications. The company also sells other branded drugs, including Imuran for use as an adjunct for the prevention of rejection in kidney transplantation and the management of active rheumatoid arthritis, Helidac Therapy for use together with an H2 antagonist for the eradication of helicobacter pylori bacteria, and Ridaura for the management of rheumatoid arthritis. In addition, Prometheus Laboratories sells a generic formulation of mercaptopurine, which is approved as maintenance therapy for acute lymphatic leukemia as part of a combination regimen through third-party distributors. Further, it provides diagnostic testing services, including specific immunoassays to detect and differentiate diseases, pharmacogenetic testing, and drug metabolite monitoring; and tests that assist physicians in using and monitoring thiopurine drugs and the detection, diagnosis, or treatment of celiac disease, lactose intolerance, and other related disorders. Prometheus Laboratories, Inc. was founded in 1995 and is headquartered in San Diego, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
6
$641.83M
Prometheus Biosciences has raised a total of $641.83M in funding over 2 rounds. Their latest funding was raised on Mar 11, 2021 from a IPO round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 11, 2021 IPO $190M Detail
Nov 9, 2020 Private Equity(PE) $130M 10 Eventide
RTW Investments
Detail
Jun 30, 2019 Series Unknown $48.06M Detail
Nov 28, 2018 Series Unknown $10.08M Detail
Oct 9, 2017 Series A $3.68M Detail

Investments

Number of Investments
Number of Lead Investments
2
0
Prometheus Biosciences has made 2 investments. Their most recent investment was on Apr 19, 2022, when Loop Health raised $25M.
Date Company Name
Round Money Raised Industry Lead Investor
Apr 19, 2022 Loop Health
Series B $25M Fitness
Jun 8, 2020 Quaise
Seed $6M Advanced Materials

Employee Profiles

Number of Employee Profiles
15
Prometheus Biosciences has 15 current employee profiles, including Executive Mark McKenna
Executive
Board member
Board member
Executive
Executive